论文部分内容阅读
目的研究临床通过NCPAP联合肺泡表面活性物质的治疗效果。方法收集我院新生儿呼吸窘迫综合征患者120例,在治疗中分为治疗组与对照组各60例,治疗组患者使用NCPAP联合肺泡表面活性物质进行治疗,对照组患者使用常规NCPAP进行治疗。结果治疗组患者的治疗效果明显优于对照组患者,P<0.05,具有统计学差异。结论在临床治疗新生儿呼吸窘迫综合征的过程中,可以使用NCPAP联合肺泡表面活性物质进行治疗,提高患者的治疗效果。
Objective To study the clinical efficacy of NCPAP in combination with alveolar surfactant. Methods 120 cases of neonatal respiratory distress syndrome in our hospital were collected and divided into treatment group and control group with 60 cases in each group. Patients in the treatment group were treated with NCPAP and alveolar surfactant, and patients in the control group were treated with conventional NCPAP. Results The therapeutic effect of the treatment group was significantly better than that of the control group, P <0.05, with statistical significance. Conclusion In the clinical treatment of neonatal respiratory distress syndrome in the process, you can use NCPAP in combination with alveolar surfactant treatment to improve the patient’s treatment.